{"id":11371,"date":"2021-08-11T19:49:19","date_gmt":"2021-08-12T00:49:19","guid":{"rendered":"http:\/\/losperiodistas.com.mx\/portal\/?p=11371"},"modified":"2021-08-11T19:49:21","modified_gmt":"2021-08-12T00:49:21","slug":"la-oms-inicia-los-ensayos-clinicos-de-tres-posibles-nuevos-tratamientos-contra-la-covid-19-ser","status":"publish","type":"post","link":"https:\/\/losperiodistas.com.mx\/portal\/la-oms-inicia-los-ensayos-clinicos-de-tres-posibles-nuevos-tratamientos-contra-la-covid-19-ser\/","title":{"rendered":"La OMS inicia los ensayos cl\u00ednicos de tres posibles nuevos tratamientos contra la COVID-19 | SER"},"content":{"rendered":"\n<p style=\"font-size:18px\"><em>Son los f\u00e1rmacos artesunate (producido por la farmac\u00e9utica Ipca), imatinib (de Novartis) e infliximab (de Johnson &amp; Johnson)<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"719\" src=\"https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2021\/08\/Captura-de-Pantalla-2021-08-11-a-las-19.45.46-1024x719.jpg\" alt=\"\" class=\"wp-image-11372\" srcset=\"https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2021\/08\/Captura-de-Pantalla-2021-08-11-a-las-19.45.46-1024x719.jpg 1024w, https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2021\/08\/Captura-de-Pantalla-2021-08-11-a-las-19.45.46-300x211.jpg 300w, https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2021\/08\/Captura-de-Pantalla-2021-08-11-a-las-19.45.46-768x539.jpg 768w, https:\/\/losperiodistas.com.mx\/portal\/wp-content\/uploads\/2021\/08\/Captura-de-Pantalla-2021-08-11-a-las-19.45.46.jpg 1532w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"has-vivid-cyan-blue-color has-text-color has-medium-font-size\">EFE \/ Ginebra \/ CADENA SER<\/p>\n\n\n\n<p>La&nbsp;<a href=\"https:\/\/cadenaser.com\/tag\/oms_organizacion_mundial_salud\/a\/\" rel=\"noreferrer noopener\" target=\"_blank\">Organizaci\u00f3n Mundial de la Salud (OMS)<\/a>&nbsp;ha anunciado el inicio de ensayos en pacientes hospitalizados con tres nuevos posibles tratamientos en los que se usar\u00e1n los f\u00e1rmacos artesunate (producido por la farmac\u00e9utica Ipca), imatinib (de Novartis) e infliximab (de Johnson &amp; Johnson). El artesunate hasta ahora era utilizado en el tratamiento de casos graves de malaria, el imatinib en algunos tipos de c\u00e1ncer, y el infliximab para la artritis reumatoide y enfermedades que atacan el sistema inmunol\u00f3gico, se\u00f1al\u00f3 la OMS en un comunicado.<\/p>\n\n\n\n<p>M\u00c1S INFORMACI\u00d3N<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li class=\"\"><a href=\"https:\/\/cadenaser.com\/ser\/2021\/07\/24\/internacional\/1627119371_759274.html?int=masinfo\" target=\"_blank\" rel=\"noreferrer noopener\">La ONU pide a China que coopere \u00abplenamente\u00bb en la investigaci\u00f3n de la OMS sobre el origen del coronavirus<\/a><\/li><li class=\"\"><a href=\"https:\/\/cadenaser.com\/ser\/2021\/07\/15\/internacional\/1626356949_355542.html?int=masinfo\" target=\"_blank\" rel=\"noreferrer noopener\">La OMS pide no administrar una tercera dosis de refuerzo: \u00abNo hay datos cient\u00edficos que la justifiquen\u00bb<\/a><\/li><li class=\"\"><a href=\"https:\/\/cadenaser.com\/ser\/2021\/07\/02\/internacional\/1625253384_096783.html?int=masinfo\" target=\"_blank\" rel=\"noreferrer noopener\">La OMS alerta de que la pandemia est\u00e1 en momento \u00abmuy peligroso\u00bb<\/a><\/li><\/ul>\n\n\n\n<p>Los tres productos han sido donados por sus fabricantes y fueron seleccionados por un panel independiente de expertos, \u00abdado su potencial a la hora de reducir el riesgo de fallecimiento en pacientes de&nbsp;<a href=\"https:\/\/cadenaser.com\/tag\/coronavirus\/a\/\" rel=\"noreferrer noopener\" target=\"_blank\">COVID-19<\/a>\u00ab, se\u00f1al\u00f3 la organizaci\u00f3n con sede en Ginebra. Con ellos se inicia la segunda fase de ensayos Solidarity, que en su primera etapa no logr\u00f3 resultados positivos tras probar en pacientes cuatro tratamientos: la hidroxicloroquina (creada inicialmente contra la malaria), el antiviral remdesivir, el interfer\u00f3n o los antirretrovirales lopinavir y ritonavir.<\/p>\n\n\n\n<p>La OMS concluy\u00f3 a finales del pasado a\u00f1o que ninguno de esos cuatro tratamientos lograba reducciones importantes en la duraci\u00f3n de las hospitalizaciones, los fallecimientos por COVID-19 o el n\u00famero de personas que requer\u00edan ventilaci\u00f3n.<\/p>\n\n\n\n<p>En contraste con el r\u00e1pido desarrollo de las vacunas anticovid, con m\u00e1s de una decena ya en uso globalmente, la OMS reconoce por ahora s\u00f3lo dos tratamientos como efectivos para los casos graves de COVID-19: la dexametasona, un corticoesteroide, y la utilizaci\u00f3n de antagonistas de interleucina-6.<\/p>\n\n\n\n<p>Mientras el primero es de f\u00e1cil acceso en todo el mundo, por el bajo precio de la dexametasona, la interleucina-6 es un tratamiento de alto coste que la propia OMS advirti\u00f3 que no estar\u00eda al alcance de la mayor\u00eda de los pacientes en pa\u00edses en desarrollo.<\/p>\n\n\n\n<p>Los ensayos Solidarity (Solidarity PLUS en esta nueva fase) involucrar\u00e1n a miles de investigadores en 600 hospitales de 52 pa\u00edses, 16 m\u00e1s que en la primera fase de pruebas, anunci\u00f3 la OMS.<\/p>\n\n\n\n<p>Fuente: https:\/\/cadenaser.com\/ser\/2021\/08\/11\/ciencia\/1628690028_038878.html<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Son los f\u00e1rmacos artesunate (producido por la farmac\u00e9utica Ipca), imatinib (de Novartis) e infliximab (de Johnson &amp; Johnson) EFE \/ [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11372,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[8],"tags":[3103,3104,3102,32,3101,3100,507],"class_list":["post-11371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","tag-imatinib","tag-infliximab","tag-ipca","tag-johnson-johnson","tag-novartis","tag-nuevos-tratamientos-covid","tag-oms"],"_links":{"self":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts\/11371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/comments?post=11371"}],"version-history":[{"count":1,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts\/11371\/revisions"}],"predecessor-version":[{"id":11373,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/posts\/11371\/revisions\/11373"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/media\/11372"}],"wp:attachment":[{"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/media?parent=11371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/categories?post=11371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/losperiodistas.com.mx\/portal\/wp-json\/wp\/v2\/tags?post=11371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}